非诺贝特治疗糖尿病视网膜病变的临床研究进展

非诺贝特是过氧化物酶增殖物激活受体α（PPAR-α）激动剂，在临床上作为调脂药物被广泛使用。它能够降低甘油三酯水平，升高高密度脂蛋白胆固醇（HDL-C）水平，降低冠脉血管事件的风险。最近的临床试验表示，非诺贝特能够延缓增殖期糖尿病视网膜病变的进展，且发现非诺贝特的这种作用与其抗炎作用等有关。现主要就非诺贝特在糖尿病视网膜病变发病中的作用及其机制进行综述。

Progress in clinical research on the beneficial effects of fenofibrate in diabetic retinopathy

Fenofibrate， which is a peroxisome proliferator-activated receptor α （PPARα） agonist， has beneficial effects on lipid profiles that include lowering triglycerides and increasing high-density lipoprotein cholesterol， and reducing coronary vascular events in large clinical trials. Results from recent clinical trials suggest a role for fenofibrate in reducing the progression and/or inducing regression in mild-to-moderate nonproliferative diabetic retinopathy （DR）. The role of fenofibrate in the pathogenesis of diabetic retinopathy is associated with its anti-inflammatory properties. The effect and mechanisms of fenofibrate in the pathogenesis of diabetic retinopathy are reviewed in this article.